Navigation Links
Curemark Moderates Autism Panel at Life Sciences Summit 2010
Date:10/11/2010

RYE, N.Y., Oct. 11 /PRNewswire/ -- Dr. Joan Fallon, founder and CEO of Curemark, LLC, (www.curemark.com), a drug research and development company focused on the treatment of neurological diseases, moderated the neuroscience roundtable focused on autism at the Life Sciences Summit 2010, held September 22-23 in Hauppauge, New York.  

Sponsored by the State University of New York at Stony Brook, Brookhaven National Laboratories and Cold Spring Harbor Laboratories, the Life Sciences Summit focused on forging partnerships between biopharmaceutical companies and companies emerging from academia to accelerate biomedical solutions in areas including infectious disease, neuroscience, oncology and regenerative medicine.   In addition to serving as panel moderator, Dr. Fallon presented an update on Curemark's autism treatment CM-AT, currently in Phase III clinical trials, at the conference's Emerging Company and Innovator's Showcase.

"The Life Sciences Summit brought together researchers, scientists and representatives of companies working at the forefront of new medical developments, who shared and exchanged ideas in this very conducive forum.  The discussion at the Roundtable highlighted some of the latest research in identifying possible causes of autism as well promising new therapies," she said.  

Participating at the Roundtable entitled "Autism Spectrum Disorder: Recent Advances in the Development of Symptomatic Treatments" were Joseph Buxbaum, PhD, MSc, principal investigator, Laboratory of Molecular Neuropsychiatry, Mount Sinai School of Medicine; Deborah A. Pearson, PhD, professor, Division of Child and Adolescent Psychiatry, Department of Psychiatry and Behavioral Sciences, University of Texas Medical School at Houston; John Spiro, PhD, senior associate director for research, Simons Foundation; and Larry J.
'/>"/>

SOURCE Curemark LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Curemark Presents at the Rodman & Renshaw Annual Global Investment Conference
2. James F. Szigethy Named Curemarks Director of New Product Development
3. Curemark to Present at BioPharm America™ 2010
4. Curemark to Present at the Rodman & Renshaw Annual Global Investment Conference
5. Curemark Opens Autism Trials at New Jersey Site
6. Curemark Begins Autism Trials at Two More Sites
7. Dr. Joan Fallon, Curemark CEO, Addresses Keystone Symposia Meeting On Autism
8. Curemark Adds UC Davis MIND Institute to Autism Clinical Trial Sites
9. Curemark CM-AT Autism Treatment Granted FDA Fast Track Status
10. Curemark Enrolling Patients In Phase III Autism Trials At Ten Sites
11. Curemark Opens Patient Enrollment for Autism Treatment at Three More Clinical Trial Sites
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... 2015  The Burzynski Research Institute, Inc. (BRI) announced ... by the Department of Surgery at Kurume University ... have been published. The study, a randomized non-blinded ... as post-operative adjuvant therapy with and without Antineoplastons ... A total of 65 patients, ...
(Date:3/26/2015)... March 26, 2015  OncoGenex Pharmaceuticals, Inc. (NASDAQ: ... clinical developments and announced fourth quarter and year ... Developments and Anticipated Near-term MilestonesCustirsen , ... to negotiate the termination of their collaboration and ... final termination agreement are ongoing. , Two ...
(Date:3/26/2015)... 2015 Over-the-counter healthcare costs can be ... a new survey of store brand over-the-counter products ... cold to diabetes, can offer significant savings for ... the Private Label Manufacturers Association, assembled a market ... those essential for treatment of pre-diabetes and diabetes. ...
Breaking Medicine Technology:OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 2OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 3OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 4OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 5OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 6OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 7OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 8Consumers can keep over-the-counter medicine affordable by using store brands 2
... 2011 Arecor Limited has entered ... Company to assess Arecor,s advanced protein formulation technologies ... biological-based drugs.  Under this agreement, Arecor will develop ... protein and peptide drug candidates developed by Lilly.  In ...
... 2011 For 64 years, The Elko ... northeast Nevada town of roughly 20,000, providing family-oriented ... pediatrics, surgical procedures and the treatment of ... latest in medical technology and equipment toward ...
Cached Medicine Technology:Arecor Forms Collaboration With Lilly to Develop Advanced Formulations of Protein Therapeutics 2MedInformatix' Practice Management and Electronic Medical Records Dramatically Speed Family Practice's Receivables, Reduce Operating Costs 2MedInformatix' Practice Management and Electronic Medical Records Dramatically Speed Family Practice's Receivables, Reduce Operating Costs 3
(Date:3/27/2015)... The report “CountryFocus: Healthcare, Regulatory and Reimbursement Landscape ... and analysis of the healthcare, regulatory and reimbursement landscape ... 2013 amounted to 316.1 million, having grown at a ... The country’s increasingly elderly population and corresponding increase in ... the growth of the pharmaceutical market, which was worth ...
(Date:3/27/2015)... 27, 2015 California’s ongoing worst ever ... Boston and the United States Northeast, are both manifestations ... global atmosphere is creating changes in the atmosphere’s “energy ... and former NASA researcher, speaking on the Sharon Kleyne ... not only a warmer and dryer global climate but ...
(Date:3/27/2015)... 27, 2015 Approximately 300 advocates ... Kids Coalition Lobby Day to lobby for physical ... Program (SHIP). Everlast Climbing was especially interested ... SF343/HF498 which would strengthen physical education programs by ... and other measures to strengthen physical education in ...
(Date:3/27/2015)... (PRWEB) March 27, 2015 Smile Brands ... providers of business support services to dental groups in ... an affiliated Castle Dental office in Hendersonville, ... Hendersonville, TN 37075, this new Castle Dental office provides ... receive the latest in comprehensive, quality dental care. Hendersonville ...
(Date:3/27/2015)... In light of two lawsuits that ... District Court, District of Massachusetts; and case number 2:15-cv-00709PD, ... Pennsylvania), the San Diego personal injury lawyers of The ... that they are available to investigate potential birth ... prescribed Zofran while pregnant and who gave birth to ...
Breaking Medicine News(10 mins):Health News:US Pharmaceutical Market worth $548.4 billion by 2020 Says a New Report Available at RnRMarketResearch.com 2Health News:US Pharmaceutical Market worth $548.4 billion by 2020 Says a New Report Available at RnRMarketResearch.com 3Health News:US Pharmaceutical Market worth $548.4 billion by 2020 Says a New Report Available at RnRMarketResearch.com 4Health News:California Drought, Boston Blizzards Both Attributed to Global Climate Change Reports Climatologist to Fresh Water Advocate 2Health News:California Drought, Boston Blizzards Both Attributed to Global Climate Change Reports Climatologist to Fresh Water Advocate 3Health News:Everlast Climbing Advocates to Strengthen Physical Education in Minnesota Schools 2Health News:Castle Dental® Opens Its First Dental Office in Hendersonville, TN 2Health News:Castle Dental® Opens Its First Dental Office in Hendersonville, TN 3Health News:The Law Office of Melinda J. Helbock, A.P.C. Announces That It Is Now Accepting Case Reviews for Potential Zofran Birth Defect Lawsuits 2
... has been shown that the drug Rimonabant (Acomplia) ... patients keep weight off // . Supplementation with 20 ... decrease in body weight and waist circumference -- a ... HDL (good) cholesterol, triglycerides, and the prevalence of metabolic ...
... cholesterol (“bad” cholesterol) to below 100 milligrams per deciliter ... is safe and results in fewer cardiovascular events. ... took 10 milligrams of atorvastatin (Lipitor) a day to ... deciliter a day or lower. Then, half of the ...
... in Spain has focused on the increasing incidence of ... associated with an increased risk of cancer in the ... been proven to have disastrous effects on the fetus ... complications such as extra uterine pregnancy, or pregnancy resulting ...
... increased recommendations for daily calcium intake, largely from dairy ... promote healthy bones and prevent osteoporosis. But a report ... milk or other dairy products was not necessarily the ... at least 400 milligrams per day. ,Other ways ...
... Most viruses, including herpes, cause both active infections and also ... no immediate infection // but can strike again whenever resistance ... those infected. ,Based on findings of a recent study ... as a treatment for a form of the herpes virus ...
... from the bone-thinning disease osteoporosis may also be at ... in which people have a difficult time digesting wheat ... bone mineral density, or BMD, among patients with both ... thinning bones, but little study exists to suggest if ...
Cached Medicine News:
The microprocessor-controlled, Norm-O-Temp® total body hyperthermia water system provides effective heat therapy at less than half the cost of a hyper-hypothermia system....
The control unit manage patient temperatures during long complex surgical procedures to help achieve optimal clinical outcomes....
... T5002 has it's temperature set by ... by pressing a button. A green ... and a flashing amber LED indicates ... temperature. A red LED and an ...
The Cocoon Convective Warming Machine is lightweight, compact and easy to use....
Medicine Products: